"covaxin"

United Nations/Geneva: A decision on Bharat Biotech’s submission seeking emergency use listing (EUL) for its Covaxin COVID-19 vaccine will be made in October, the World Health Organisation has said. The status of assessment for Covaxin is “ongoing”. Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine. The latest ‘Status of […]

Hyderabad: The Council of Scientific & Industrial Research (CSIR) – Indian Institute of Chemical Technology (IICT), Hyderabad, team led by director Dr. S Chandrasekhar has been awarded the CSIR Technology Award 2021 for outstanding contributions to the affordable healthcare. The team has developed a cost-effective and scalable process for the synthesis of TLR 7/8 agonist […]

New Delhi: The Co-founder and Joint Managing Director of Hyderabad-based Bharat Biotech, Suchitra Ella has said that vaccines should not be a barrier to enter into any nation. Amid the ongoing row over new UK travel restrictions that consider fully Indian vaccinated as unvaccinated and prescribes 10-day quarantine, she said, “Vaccines must not be entry […]

Hyderabad: Bharat Biotech completed the Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said on Tuesday here. Speaking to reporters, he said Covaxin […]

Union minister of Health and Family Welfare Mansukh Mandaviya formally launched the Covaxin batches. Dr Krishna Ella, CMD, Bharat Biotech and Suchitra Ella, joint managing director, Bharat Biotech were also present at the launch.

Nod for Zydus Cadila'd Covid vaccine for children will help India ramp up its vaccination programme quickly

Output of Covaxin drug substance will be adequate for 3 to 4 million doses a month and from December it will increase to 10 million doses a month

It is argued that such a mixed regimen will help overcome the challenges of the shortfall of certain vaccines and remove hesitancy, especially in settings where multiple Covid-19 vaccines are being used

An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on July 29 had recommended granting permission for conducting the study.

Bharat Biotech recently stated that products manufactured from Ankleshwar will be available for supplies during September.

Under the special freedom offer, Apollo Hospitals will offer the Covaxin vaccine at a no profit cost price of Rs.1,250.

The results of a study conducted by ICMR showed that the people in the mix and match group had superior immunogenicity profiles against Alpha, Beta and Delta variants of Covid-19

Ocugen said Bharat Biotech completed and posted its phase 3 clinical trial results for Covaxin demonstrating 77.8 per cent efficacy against overall Covid-19 disease

Says supply of nearly 70 million doses of its Covid-19 vaccine to date proves its safety standards

The approval has been received from the National Institute of Pharmacy and Nutrition, Hungary, certifying the GMP for the manufacture of Covaxin.

More than half of the adult population has yet to receive even a single dose, despite a slight improvement in coverage in July

The company had supplied about four billion doses to about 125 countries and will continue to ramp up production at its four plants in the country, said Suchitra Ella, co-founder of Bharat Biotech

The rate of mortality was found to be about 50% lower in fully vaccinated individuals having a breakthrough infection, according to CCMB, AIg study

The analysis of breakthrough cases is a clear indication that vaccines are the best bet to reduce severity and fatalities among Covid-19 patients.

Speaking at a webinar organised by the Centre for Science and Environment (CSE) on Friday, Swaminathan said the WHO is reviewing Covaxin as its manufacturer Bharat Biotech is now uploading its entire data